EMEA-003362-PIP01-22 - paediatric investigation plan

xalnesiran

Key facts

• Active Substance:
  xalnesiran
• Therapeutic area:
  Infectious diseases
• Decision number:
  P/0435/2023
• PIP number:
  EMEA-003362-PIP01-22
• Pharmaceutical form(s):
  Solution for injection
• Condition(s) / indication(s):
  Treatment of chronic hepatitis B
• Route(s) of administration:
  Subcutaneous use
• Decision type:
  P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
• Decision date:
  27/10/2023

Decision

P/0435/2023 : EMA decision of 27 October 2023 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for xalnesiran, (EMEA-003362-PIP01-22)

AdoptedReference Number: EMA/470007/2023